ADG116 + ADG106

ADG116 + ADG106 is an investigational combination of two distinct antibody therapies for cancer immunotherapy. **ADG116** is a fully human monoclonal antibody that targets CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4), designed to enhance immune responses by depleting regulatory T cells (Tregs) within the tumor microenvironment while preserving peripheral immune homeostasis with a unique epitope and soft ligand blocking mechanism. **ADG106** is a fully human, ligand-blocking, agonistic monoclonal antibody targeting CD137 (4-1BB), a costimulatory receptor on immune cells; it activates and proliferates T cells and NK cells to induce anti-tumor immunity. Preclinical and early-phase clinical studies have demonstrated synergistic anti-tumor effects when used together, supporting further investigation in advanced/metastatic solid tumors. Both antibodies are developed using Adagene's proprietary NEObody platform. The combination is being evaluated in early clinical trials for safety and preliminary efficacy against advanced solid tumors[2][3][5][7].